Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report

Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance. Detection of mutations is helpful in clinical management of imatinib resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, Zafar, Siddiqui, Rubina T., Qureshi, Javed A.
Formato: Texto
Lenguaje:English
Publicado: Biological Procedures Online 2004
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC443563/
https://www.ncbi.nlm.nih.gov/pubmed/15243647
http://dx.doi.org/10.1251/bpo83

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC443563/
https://www.ncbi.nlm.nih.gov/pubmed/15243647
http://dx.doi.org/10.1251/bpo83

Ejemplares similares